BiotechTube

Atacicept + Placebo matched to atacicept

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Optic Neuritis

Conditions

Optic Neuritis

Trial Timeline

Jun 1, 2008 → Jan 1, 2011

NCT ID
NCT00624468

About Atacicept + Placebo matched to atacicept

Atacicept + Placebo matched to atacicept is a phase 2 stage product being developed by Merck for Optic Neuritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00624468. Target conditions include Optic Neuritis.

What happened to similar drugs?

4 of 14 similar drugs in Optic Neuritis were approved

Approved (4) Terminated (4) Active (8)
✅Satralizumab 120 mgChugai PharmaceuticalApproved
🔄Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3
🔄Satralizumab + PlaceboChugai PharmaceuticalPhase 3
🔄satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3
🔄SatralizumabRochePhase 3
✅InebilizumabAmgenApproved
❌Zyvox - linezolid + Matched controlPfizerPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00624468Phase 2Terminated

Competing Products

20 competing products in Optic Neuritis

See all competitors
ProductCompanyStageHype Score
Satralizumab 120 mgChugai PharmaceuticalApproved
35
Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3
40
Satralizumab + PlaceboChugai PharmaceuticalPhase 3
40
PDE5 InhibitorsEli LillyPre-clinical
26
Fingolimod 0.5mg/daily + PlaceboNovartisPhase 2
27
satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3
40
SatralizumabRochePhase 3
47
UPLIZNAAmgenPre-clinical
33
InebilizumabAmgenPhase 2
42
InebilizumabAmgenApproved
47
Zyvox - linezolid + Matched controlPfizerPhase 3
32
Dexmedetomidine HCL Injection + PlaceboPfizerPhase 3
40
No interventionPfizerPre-clinical
26
Efgartigimod Alfa + PlaceboArgenxPhase 2
39
Diagnostic proceduresBayerApproved
32
Placebo + BIIB033 100mg/KgBiogenPhase 2
32
BIIB033 (anti-LINGO-1 mAb) + PlaceboBiogenPhase 2
32
intravenous methylprednisoloneBrain BiotechPre-clinical
23
OCS-05 +SoC (corticosteroid) IV administrationOculis Holding AGPhase 2
29
EVO756 + EVO756 + EVO756 + Placebo controlEvommunePhase 2
36